How to Talk to Your Doctor About Peptides Without the Conversation Stalling

Compounded peptide prescribing is not taught in general medical training and does not appear in the guidelines primary care runs on. A family physician manages hypertension, diabetes, depression and musculoskeletal complaints from evidence bases with thousands of enrolled patients behind them; nothing in that work creates an occasion to read the BPC-157 literature. An unfamiliar answer is not an uninformed one, and "I do not know enough about that to prescribe it" is an accurate statement.

This is what most patient-facing writing on the subject gets wrong. These molecules do not share one evidence base; they sit at very different points on the same scale, and your physician's reaction usually depends on which one you named. Semaglutide and tirzepatide have large randomised programmes in the New England Journal of Medicine. BPC-157 and TB-500 rest on animal and cell work. A clinician engaged by the first pair and unmoved by the second is not being inconsistent — they are reading the evidence correctly.

There is real data on this. A randomised trial published in JAMA in 2005 sent standardised patients into primary-care visits and found that a patient's request for a specific advertised medication had a large effect on whether it was prescribed, including in encounters where prescribing was not clearly indicated. Physicians know this about themselves. Part of the resistance you meet when you open with a product name is a clinician deliberately resisting a pressure they have been trained to recognise — on top of having seen patients arrive with pages promising specific outcomes on specific timelines. Leading with the problem removes the pressure and gets you a real opinion.

Not "a healing peptide." The molecule, the concentration, the volume and the directions exactly as printed: BPC-157 1 mg/mL in a 5 mL vial, say, or semaglutide at the strength on your own label. Read the directions off the vial rather than from memory. A clinician cannot assess a dose they cannot reconstruct, and "one shot a day" is not a dose.

Name the prescribing physician, the state they are licensed in, and the pharmacy that compounded it. Not a formality: it tells your own doctor that a named clinician holds responsibility for the prescription and that the vial traces back to an accountable, inspected facility — which is what section 503A is built around, a preparation made by a licensed pharmacist or physician for an identified individual patient pursuant to a valid prescription. A preparation with no nameable pharmacy behind it is what your physician is actually worried about, and rightly.

A COA is the batch test document: identity, purity, and sterility and endotoxin testing for an injectable. It answers directly what approval does not answer for a compounded drug, because the FDA's framing of the risk is about preparation quality — "Poor compounding practices can result in serious drug quality problems, such as contamination or a drug that contains too much or too little active ingredient." A COA moves you from asserting that your medication is what the label says to demonstrating it. Pepti publishes batch results at lab results and the testing programme at quality.

Recent bloodwork with dates, and the previous set if you have it — two data points separated by time are worth far more than one. Many of the complaints that lead people to peptides, including fatigue, low mood, hair shedding and poor recovery, are explained by thyroid, iron, B12 or testosterone before anything else is considered. Do you need bloodwork before peptides covers what is usually ordered, and at-home blood testing covers hormone, metabolic and thyroid panels without a lab visit.

What, where, how long, what makes it worse. Two sentences, rehearsed. A secondary analysis of recorded primary-care encounters published in the Journal of General Internal Medicine in 2019 found that where clinicians did elicit the patient's agenda, they interrupted after a median of about eleven seconds. That is simply how the encounter runs, so your first eleven seconds should carry the problem, not the preamble.

Rehabilitation, imaging, previous treatments, what helped and what did not. This is the step that turns a complaint into a clinical problem, and the one most people skip. "Six months of eccentric loading with a physiotherapist, initial improvement, plateaued since March" is a history. "I have tried everything" is not.

Genuinely ask, then leave a silence. A physician who has been consulted rather than instructed engages differently, and you find out whether there is a conventional option you have not been offered — which for tendinopathy and for weight there frequently is.

"I have been reading about BPC-157 and TB-500. Given my history and my medications, is there a reason I should not?"

That is a safety question, not a request. Prescribing is discretionary and scope-bound; advising a patient about risk is neither, which is why this version rarely meets resistance and survives a firm refusal to prescribe. A doctor who will not write BPC-157 can still tell you that your anticoagulant, your cancer history or your planned surgery changes the picture.

The question that pays off, and almost nobody asks it. Even a physician who will not prescribe can usually tell you which labs would be sensible, what symptom would make them want to see you, and what they would want repeated in three months. That is a monitoring plan from someone who knows your history — often worth more than the prescription you came in for.

A tendon that has not settled. "My right Achilles has been painful for eight months. Six months of eccentric loading with a physiotherapist helped for about eight weeks, then plateaued. Ultrasound in March showed thickening, no tear. What would you suggest at this point?" Then, after the answer: "I have been reading about BPC-157. Given my history, is there a reason I should not — and if I did, what would you want monitored?"

Fatigue. "I have been flat for five months. I sleep seven hours and wake unrefreshed, and I have lost the top of my training capacity. My last bloods were eighteen months ago. I would like to know whether there is something to find before I consider anything else." That gets labs ordered; opening with a product name usually does not.

You have already started. "I started semaglutide through a telehealth physician two months ago — here is the vial, the strength, the prescriber's name and the pharmacy. I am not asking you to take it over. I want it on my record, and I want to know what you would monitor." Short conversation, and the most valuable version of this discussion you will ever have.

Clinicians do not sort studies into "there is research" and "there is none." They grade certainty. The framework most guideline bodies use is GRADE, set out in the BMJ in 2008, which starts randomised trials at high certainty and observational work at low, then adjusts for risk of bias, imprecision, inconsistency and indirectness. Indirectness is the word that matters: evidence in rats about rat tendons is indirect evidence about your tendon, however large the effect. When your doctor says "there is no good evidence," they usually mean it is indirect — a more specific objection, and a more answerable one.

Two papers explain the reflex. A 2006 review in JAMA examined highly cited animal studies and found only a minority were later replicated in human randomised trials, with a substantial share contradicted. A systematic review in the BMJ in 2007 compared treatment effects between animal experiments and the corresponding clinical trials across six interventions and found agreement in only some. That is the whole basis of the caution you are meeting: not prejudice about peptides, but a general and well-supported position about preclinical data. Saying it out loud — "I know animal data translates poorly, and I am not treating it as proof" — does more for your credibility than any study you could quote.

Do not understate this half, because it is where most physicians will meet you. Semaglutide has a large randomised programme, including the STEP 1 weight-management trial in the New England Journal of Medicine in 2021 and cardiovascular outcome data in the same journal. Tirzepatide has SURMOUNT-1, also in the New England Journal of Medicine, in 2022, plus randomised work in obstructive sleep apnoea. Tesamorelin has randomised placebo-controlled trials in HIV-associated abdominal fat accumulation — the pivotal one in the New England Journal of Medicine in 2007, later work in JAMA and Lancet HIV. Sermorelin, as GHRH(1-29), carries decades of endocrine literature, including a randomised controlled trial of GHRH and cognitive outcomes in older adults in Archives of Neurology in 2012.

Describing semaglutide, tirzepatide, tesamorelin and sermorelin accurately — including that those trials were run on branded manufactured products, and that a compounded preparation shares the active ingredient and not the approval — marks you out as someone who has read the literature rather than the marketing.

BPC-157, TB-500, KPV, MOTS-c and epithalon are, for the indications people ask about, supported by animal and cell research rather than large randomised human trials. There are no randomised controlled trials of BPC-157 in humans for tendon or soft-tissue injury, and none of TB-500 for the uses it is asked about, although its parent molecule thymosin beta-4 has been through early-phase human work. GHK-Cu is the partial exception: the GHK-Cu literature is the deepest of the repair peptides, going back to collagen-synthesis work in FEBS Letters in 1988, and much of the later connective-tissue work is in humans, though largely topical rather than injectable. Saying all of this before your physician has to is the most effective move available to you, and it costs you nothing that was ever true. What is BPC-157, what is TB-500 and what is GHK-Cu set out what each body of work does and does not establish.

The FDA announced on 15 April 2026 that it would remove twelve peptide bulk drug substances from Category 2 of its 503A interim policy — the category for substances that "may present significant safety risks." The current Category 2 list, updated 22 April 2026, no longer includes BPC-157, TB-500, KPV, MOTS-c, Semax or epitalon. If your physician has read a 2023-era summary describing BPC-157 as a Category 2 substance, that summary is now out of date.

The FDA's Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to consider several peptides for the 503A Bulks List. It voted to recommend BPC-157, KPV, TB-500 and MOTS-c on 23 July, and Semax and epitalon on 24 July; it did not recommend emideltide. Those are advisory recommendations, not decisions. Adding a substance to the list requires notice-and-comment rulemaking, and the FDA's final determination is still pending.

Not everything moved: ipamorelin acetate and kisspeptin-10 remain in Category 2 on the current list, alongside GHRP-2 and GHRP-6. The accurate one-sentence version to bring into the room: "Most of the repair peptides were removed from the FDA's safety-risk category in April 2026 and were recommended for the positive list by the advisory committee in July, but the final rule has not been issued, and compounded medications are not FDA approved in any case."

"I do not write those" is a statement about the physician's practice, not a finding about your body, and it carries no information about whether the treatment suits you — which is exactly why the safety and monitoring questions still need asking. A refusal with no reason gives you even less; ask one follow-up, "is that about me, or about the medication?", because the answer tells you which of the other rows you were actually given. Then take the monitoring answers and leave it there. Pushing further in that visit does not work.

"I do not think this is appropriate for you" is the one to slow down for. Ask what specifically — the family history, a medication, a lab value, a planned procedure, a diagnosis. A clinical objection is about you, it follows you to any other prescriber, and a careful telehealth physician reading the same intake will often reach the same conclusion independently. Getting the reason written down beats getting a second opinion.

"There is no good evidence for that" is accurate for several of these molecules, so say so, then ask what they would do instead. For a plateaued tendinopathy that may be a different loading protocol, an imaging review or a sports-medicine referral, all better evidenced than any peptide. "Let us check some labs first" is the response most worth complying with: fatigue, low mood, poor recovery and hair shedding are explained by thyroid disease, iron deficiency, B12 deficiency or low testosterone often enough that testing first is simply good medicine. Normal labs send you back with a stronger case, not a weaker one.